June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Relationship between Retinal Structural Abnormalities and Visual Outcomes in the Phase 2 Boulevard Trial for Diabetic Macular Edema
Author Affiliations & Notes
  • Siva Balasubramanian
    Genentech Inc, South San Francisco, California, United States
  • Dinah Chen
    Genentech Inc, South San Francisco, California, United States
  • Qi Yang
    Genentech Inc, South San Francisco, California, United States
  • Yusuke Kikuchi
    Genentech Inc, South San Francisco, California, United States
  • Kumar Surulisamy
    Genentech Inc, South San Francisco, California, United States
  • Carlos Quezada Ruiz
    Genentech Inc, South San Francisco, California, United States
  • Footnotes
    Commercial Relationships   Siva Balasubramanian Genentech, Code E (Employment); Dinah Chen Genentech, Code C (Consultant/Contractor); Qi Yang Genentech, Code E (Employment); Yusuke Kikuchi Genentech, Code E (Employment); Kumar Surulisamy Genentech, Code E (Employment); Carlos Ruiz Genentech, Code E (Employment)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2702. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Siva Balasubramanian, Dinah Chen, Qi Yang, Yusuke Kikuchi, Kumar Surulisamy, Carlos Quezada Ruiz; Relationship between Retinal Structural Abnormalities and Visual Outcomes in the Phase 2 Boulevard Trial for Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2702.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Diabetic macular edema (DME) leads to significant vision impairment among people with Diabetic retinopathy (DR). Previous optical coherence tomography (OCT) studies have confirmed retinal structural abnormalities in DME. We investigated the relationship between individual retinal structural abnormalities and visual function in the phase 2 Boulevard trial (NCT02699450) for DME.

Methods : Eligible patients from the phase 2 Boulevard trial were included. A total of 142 eyes from 142 subjects were evaluated at baseline (BL) and week 36 (w36) visits. Subjects underwent eye examinations including best-corrected visual acuity (BCVA) and Heidelberg Spectralis OCT imaging. Inner retinal layers (Figure 1) including inner plexiform layer-inner nuclear layer (IPL-INL), inner nuclear layer-outer plexiform layer (INL-OPL), outer plexiform layer-outer nuclear layer (OPL-ONL) and outer retinal layers including ellipsoid zone (EZ) and external limiting membrane (ELM) were manually evaluated for presence or absence of layer disruptions on a central horizontal B-scan.

Results : Multiple linear regression model analysis identified disrupted external limiting membrane (dELM) at BL as a significant predictor of logMAR BCVA (p=0.001) at w36. Among the OCT features at BL, dELM and disrupted EZ (dEZ) were significantly (p<0.001) associated with logMAR BCVA at BL. At w36 there was no significant association between logMAR BCVA and retinal structural abnormalities. Point biserial correlation analysis showed significant negative correlation between logMAR BCVA and dELM (p < 0.001) and dEZ (p < 0.001) at BL.

Conclusions : The inner and outer retinal layers appear to be profoundly altered and associated with impaired vision. In particular, dELM was associated with worse visual outcomes. Further longitudinal studies in DME are required to study these retinal changes and its response to treatment over time.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

 

Figure 1. Disrupted inner (IPL-INL, INL-OPL, OPL-ONL) and outer retinal layers (ELM, EZ)

Figure 1. Disrupted inner (IPL-INL, INL-OPL, OPL-ONL) and outer retinal layers (ELM, EZ)

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×